Clinical Practice Session
Practical Considerations in the Use of Genetic Testing for APOL1 Kidney Risk Variants
October 25, 2026 | 09:30 AM - 11:30 AM
Location: Mile High Ballroom 1D, Convention Center
Session Description
Testing for APOL1 kidney risk variants is now available through many research and clinical laboratories. This session explores the indications for testing for risk alleles; consent for genetic testing; and the medical, ethical, legal, and social implications of genetic testing.
Learning Objective(s)
- Identify where and how to obtain genetic testing for APOL1 kidney risk variants
- Describe the key elements of informed consent in genetic testing for APOL1 kidney risk variants
- Identify individuals who may benefit from genetic testing for APOL1 kidney risk variants
- Discuss the clinical implications of having one or two APOL1 risk variants, considering the patient's phenotype and exposomic profile
- Discuss the ethical, legal, and social implications of having one or two APOL1 kidney risk variants
Learning Pathway(s)
- CKD Non-Dialysis
- Genetic Diseases and Development
Moderators
Presentations
- Genetic Testing for APOL1 Kidney Risk Variants: Who, When, and Where?
09:30 AM - 10:00 AM
- Shared Decision-Making in APOL1 Genetic Testing and Interpretation of Results
10:00 AM - 10:30 AM
- Spectrum of APOL1-Mediated Kidney Disease States: Controversies and Knowledge Gaps
10:30 AM - 11:00 AM
- Ethical, Legal, and Socioeconomic Implications of APOL1 Genetic Testing
11:00 AM - 11:30 AM